ALEC Quote, Financials, Valuation and Earnings

Precision BioSciences has a net margin of -275.19% compared to Alector's net margin of -2851.56%. Alector's return on equity of -106.3% beat Precision BioSciences's return on equity of 19.19%.

Alector has a consensus price target of $5.51, signalling upside risk potential of 196.37%. On the other hand Precision BioSciences has an analysts' consensus of $33.60 which suggests that it could grow by 601.46%. Given that Precision BioSciences has higher upside potential than Alector, analysts believe Precision BioSciences is more attractive than Alector.

Alector has a beta of 0.506, which suggesting that the stock is 49.353% less volatile than S&P 500. In comparison Precision BioSciences has a beta of 1.408, suggesting its more volatile than the S&P 500 by 40.772%.

Alector has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precision BioSciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector pays -- of its earnings as a dividend. Precision BioSciences pays out -- of its earnings as a dividend.

Alector quarterly revenues are $15.3M, which are larger than Precision BioSciences quarterly revenues of $576K. Alector's net income of -$42.2M is lower than Precision BioSciences's net income of -$16.4M. Notably, Alector's price-to-earnings ratio is -- while Precision BioSciences's PE ratio is 79.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector is 2.82x versus 0.37x for Precision BioSciences. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -275.19% compared to Alector's net margin of -49.65%. Alector's return on equity of -106.3% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Alector has a consensus price target of $5.51, signalling upside risk potential of 196.37%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that NovaBay Pharmaceuticals has higher upside potential than Alector, analysts believe NovaBay Pharmaceuticals is more attractive than Alector.

Alector has a beta of 0.506, which suggesting that the stock is 49.353% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Alector has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Alector quarterly revenues are $15.3M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Alector's net income of -$42.2M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Alector's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector is 2.82x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Poseida Therapeutics has a net margin of -275.19% compared to Alector's net margin of 28.2%. Alector's return on equity of -106.3% beat Poseida Therapeutics's return on equity of -66.05%.

Alector has a consensus price target of $5.51, signalling upside risk potential of 196.37%. On the other hand Poseida Therapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 0.32%. Given that Alector has higher upside potential than Poseida Therapeutics, analysts believe Alector is more attractive than Poseida Therapeutics.

Alector has a beta of 0.506, which suggesting that the stock is 49.353% less volatile than S&P 500. In comparison Poseida Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Alector has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Poseida Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector pays -- of its earnings as a dividend. Poseida Therapeutics pays out -- of its earnings as a dividend.

Alector quarterly revenues are $15.3M, which are smaller than Poseida Therapeutics quarterly revenues of $71.7M. Alector's net income of -$42.2M is lower than Poseida Therapeutics's net income of $20.2M. Notably, Alector's price-to-earnings ratio is -- while Poseida Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector is 2.82x versus 6.07x for Poseida Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -275.19% compared to Alector's net margin of -2357.27%. Alector's return on equity of -106.3% beat Palatin Technologies's return on equity of --.

Alector has a consensus price target of $5.51, signalling upside risk potential of 196.37%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Palatin Technologies has higher upside potential than Alector, analysts believe Palatin Technologies is more attractive than Alector.

Alector has a beta of 0.506, which suggesting that the stock is 49.353% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Alector has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Alector quarterly revenues are $15.3M, which are larger than Palatin Technologies quarterly revenues of $350K. Alector's net income of -$42.2M is lower than Palatin Technologies's net income of -$7.8M. Notably, Alector's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector is 2.82x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.